SAN FRANCISCO - Companies in the cell and gene therapy space are witnessing historic levels of fundraising as enthusiasm spikes over the potential of new therapeutic products in the sector. This is leading to a shift in the landscape for mergers and acquisitions, where companies with little to no track records are commanding astronomical valuations, according to a Tuesday presentation at this week's J.P. Morgan Healthcare Conference.
